<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740415</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000589544</org_study_id>
    <secondary_id>-MANTEAU-2010-SA</secondary_id>
    <nct_id>NCT00740415</nct_id>
  </id_info>
  <brief_title>Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma</brief_title>
  <acronym>ManteauRiBVD</acronym>
  <official_title>First-line Treatment of Mantle Cell Lymphoma of Old Patients . Evaluate the Efficacy, Toxicity, and Molecular Prognostic Factors of Velcade®) in Association With Chemotherapy and Immunotherapy With Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mundipharma Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
      help kill them or carry cancer-killing substances to them. Bortezomib may stop the growth of
      cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood
      flow to the tumor. Drugs used in chemotherapy, such as doxorubicin, dexamethasone, and
      chlorambucil, work in different ways to stop the growth of cancer cells, either by killing
      the cells or by stopping them from dividing. Giving combination chemotherapy together with
      rituximab and bortezomib may kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving rituximab together with bortezomib,
      doxorubicin, dexamethasone, and chlorambucil works as first-line therapy in treating older
      patients with stage II, stage III, or stage IV mantle cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the efficacy of rituximab, bortezomib, doxorubicin hydrochloride,
           dexamethasone, and chlorambucil as first-line therapy in patients with stage II-IV
           mantle cell lymphoma.

      Secondary

        -  Determine the complete response rate in these patients.

        -  Determine the efficacy, in terms of complete and overall response, by F18
           fludeoxyglucose scan.

        -  Determine overall, disease-free, and event-free survival of these patients.

        -  Assess tolerability of this regimen in these patients.

        -  Evaluate the impact of factors, described in previous protocols, on response to therapy
           and survival.

        -  Assess the impact of residual disease in cerebrospinal fluid on survival.

      OUTLINE: This is a multicenter study.

      Patients receive rituximab IV on day 1 (days 1 and 8 of the first course only); bortezomib IV
      on days 1, 4, 8, and 11; doxorubicin hydrochloride IV continuously over 24 hours on days 1-4;
      dexamethasone IV on days 1-4; and oral chlorambucil on days 20-29. Treatment repeats every 5
      weeks for 4 courses in the absence of disease progression or unacceptable toxicity.

      Patients who achieve at least 50% response receive 2 additional courses of therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate after 4 courses of therapy</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>ARM RiBVD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RiBVD 6 cycles every 28 days day 1 :
Rituximab /Mabthera®, 375 mg/m2 en IV
Bendamustine, 90 mg/m2 en IVD
Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 2 : - Bendamustine, 90 mg/m2 en IVD
Dexamethasone, 40 mg IV day 4 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 8 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 11 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Rituximab, 375 mg/m2 Intraveinous</description>
    <arm_group_label>ARM RiBVD</arm_group_label>
    <other_name>Mabthera ®,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11</description>
    <arm_group_label>ARM RiBVD</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>day - Dexamethasone, 40 mg Intraveinous</description>
    <arm_group_label>ARM RiBVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous</description>
    <arm_group_label>ARM RiBVD</arm_group_label>
    <other_name>Levact ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of mantle cell lymphoma

               -  Stage II-IV disease

          -  No neuromeningeal disease

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  No prior cancer except for carcinoma in situ of the cervix or basal cell skin cancer

          -  LVEF &gt; 50%

          -  HIV-negative

          -  Hepatitis B- and C-negative

          -  No hepatocellular, renal, or bone marrow insufficiency unrelated to lymphoma

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remy Gressin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de Grenoble - Hopital de la Tronche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO website</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

